ClinicalTrials.gg
CompletedNCT00761215Updated Nov 25, 2019Results posted

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

A Phase 2 interventional study of TR-701 200 mg and TR-701 300 mg in Skin Diseases, Infectious and Skin Diseases, Bacterial, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-11-25.

Primary conditionSkin Diseases, BacterialRegistry: Skin Diseases, InfectiousReclassifiedWhy we changed it
Registry
Skin Diseases, Infectious — the first condition term the registry derived for this study.
ClinicalTrials.gg
Skin Diseases, Bacterial
Why
  1. The study's listed conditions name Skin Diseases, Bacterial, a narrower term within Skin Diseases, Infectious.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Skin Diseases, Bacterial with a site in United States — 1 open to participants now, 2 under way, 1 of them phase 3. Skin Diseases, Bacterial · United States.

Enrollment
15th of 21
192 · median 234
Started
2008
with 1 other
Phase 2
9 of 22
none open now
Registered
8th of 22
by date

Among the 22 studies in Skin Diseases, Bacterial with a site in United States, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2008, is one of 9 in phase 2, and was the 8th registered.

Skin Diseases, Bacterial

37 studies on the registry are indexed under Skin Diseases, Bacterial; 2 are open to participants now.

Browse Skin Diseases, Bacterial studies →

Open to participants now

1 of the 22 studies in Skin Diseases, Bacterial with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1 Skin Diseases, Bacterial study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Skin Diseases, Bacterial with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.

03

Conditions studied

  • Skin Diseases, Infectious
  • Skin Diseases, Bacterial

Browse trials for

Keywords

  • Skin
  • Infection
  • Complicated Skin and Skin Structure Infection
04

In context

Skin Diseases, Bacterial Reclassified

37 studies on the registry are indexed under Skin Diseases, Bacterial; 2 are open to participants now.

This study's enrollment of 192 is below the median of 249 across 29 interventional studies indexed under Skin Diseases, Bacterial.

Browse Skin Diseases, Bacterial studies →

Lead sponsor

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc.

Compared within Skin Diseases, Bacterial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases, Infectious. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with complicated skin and skin structure infection with at least 2 signs and symptoms
  • Suspected or confirmed infection due to a gram-positive organism

Exclusion criteria

Exclusion Criteria:

  • Complicated skin and skin structure infection due to gram-negative organisms
  • Complicated skin and skin structure infections requiring more than 7 days of therapy
  • Uncontrolled diabetes
  • Chronic systemic therapy
  • AIDS with \< 200 cells/mm3
  • Uncontrolled hypertension
  • Mild moderate or severe renal failure
  • Severe hepatic disease
  • Neutropenia
  • Use of antidepressants such as SSRIs or MAOIs for 14 days before first dose of study drug
  • Women who are pregnant or nursing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    TR-701 200 mg

    Drug: TR-701 200 mg

  • Experimental
    TR-701 300 mg

    Drug: TR-701 300 mg

  • Experimental
    TR-701 400 mg

    Drug: TR-701 400 mg

Interventions

07

What researchers measure

Primary outcomes

  1. Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set

    Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.

    Time frame: 7 to 14 days after the last dose of study drug

  2. Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set

    Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.

    Time frame: 7-14 days after last dose of study drug

Secondary outcomes

  1. Response Rate at End of Therapy

    Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.

    Time frame: last day of study treatment

  2. Microbiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set

    Satisfactory microbiological outcomes are eradication and presumed eradication

    Time frame: 7-14 days after last dose of study drug

  3. Clinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set

    Persistent clinical cure was defined as continuing favorable response.

    Time frame: 21 to 28 days after the last study drug

  4. To Evaluate the Safety Profile of Tedizolid Phosphate

    Time frame: Multiple

  5. Population PK

    Time frame: Multiple

  6. Microbiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set

    Time frame: 21-28 days after last study drug

08

Results

Posted Aug 7, 2014

Participant flow

Participant flow — Overall Study
MilestoneTR-701 200 mgTR-701 300 mgTR-701 400 mg
Started646464
Completed556056
Not completed948
Withdrew: Randomized but didn't receive drug112
Withdrew: Lost to follow-up636
Withdrew: Withdrawal by subject100
Withdrew: Bacteremia100

Outcome measures

PrimaryClinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set

Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.

Time frame:
7 to 14 days after the last dose of study drug
Reported as:
Number · Percentage of participants
Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set
Percentage of participantsTR-701 200 mgTR-701 300 mgTR-701 400 mg
Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set98.2 (90.4 to 100)94.4 (84.6 to 98.8)94.4 (84.6 to 98.8)
PrimaryClinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set

Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.

Time frame:
7-14 days after last dose of study drug
Reported as:
Number · Percentage of participants
Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set
Percentage of participantsTR-701 200 mgTR-701 300 mgTR-701 400 mg
Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set88.9 (78.4 to 95.4)88.9 (78.4 to 95.4)85.5 (74.2 to 93.1)
SecondaryResponse Rate at End of Therapy

Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.

Time frame:
last day of study treatment
Reported as:
Number · Percentage of participants
Response Rate at End of Therapy
Percentage of participantsTR-701 200 mgTR-701 300 mgTR-701 400 mg
Response Rate at End of Therapy93.7 (84.5 to 98.2)90.5 (80.4 to 96.4)91.9 (82.2 to 97.3)
SecondaryMicrobiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set

Satisfactory microbiological outcomes are eradication and presumed eradication

Time frame:
7-14 days after last dose of study drug
Reported as:
Number · Percentage of participants
Microbiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set
Percentage of participantsTR-701 200 mgTR-701 300 mgTR-701 400 mg
Microbiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set100 (91.8 to 100)93.2 (81.3 to 98.6)100 (92.3 to 100.0)
SecondaryClinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set

Persistent clinical cure was defined as continuing favorable response.

Time frame:
21 to 28 days after the last study drug
Reported as:
Number · Percentage of Participants
Clinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set
Percentage of ParticipantsTR-701 200 mgTR-701 300 mgTR-701 400 mg
Clinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set96.498.298.1
SecondaryTo Evaluate the Safety Profile of Tedizolid Phosphate
Time frame:
Multiple

Results for this outcome have not been posted.

SecondaryPopulation PK
Time frame:
Multiple

Results for this outcome have not been posted.

SecondaryMicrobiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set
Time frame:
21-28 days after last study drug
Reported as:
Number · Percentage of participants
Microbiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set
Percentage of participantsTR-701 200 mgTR-701 300 mgTR-701 400 mg
Microbiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set0 (0 to 6.4)0 (0 to 6.4)0 (0 to 6.7)

Adverse events

Collected over Adverse events were to be collected after informed consent through last visit (up to 36 days).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TR-701 200 mg—2/63 (3.2%)40/63 (63.5%)
TR-701 300 mg—1/63 (1.6%)44/63 (69.8%)
TR-701 400 mg—2/62 (3.2%)43/62 (69.4%)
Most frequent serious events
Most frequent serious events
EventTR-701 200 mgTR-701 300 mgTR-701 400 mg
Suicidal ideationPsychiatric disorders0/630/631/62
AbcessInfections and infestations1/630/631/62
Cholecystitis acuteHepatobiliary disorders0/631/630/62
CellulitisInfections and infestations1/630/630/62
Most frequent other events
Showing 10 of 20
Most frequent other events
EventTR-701 200 mgTR-701 300 mgTR-701 400 mg
NauseaGastrointestinal disorders10/6312/6313/62
HeadacheNervous system disorders5/6310/636/62
AbscessInfections and infestations5/638/637/62
DiarrheaGastrointestinal disorders7/633/636/62
VomitingGastrointestinal disorders7/636/636/62
Skin infectionInfections and infestations4/632/632/62
Blood pressure increasedInvestigations1/634/632/62
DizzinessNervous system disorders4/631/630/62
InsomniaPsychiatric disorders1/634/631/62
Skin lesionSkin and subcutaneous tissue disorders4/632/631/62

Baseline characteristics

All randomized participants who received study drug.

Age, Continuous
Age, Continuous(years)TR-701 200 mgTR-701 300 mgTR-701 400 mgTotal
Mean37.3 ± 12.136.0 ± 12.435.8 ± 12.036.4 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)TR-701 200 mgTR-701 300 mgTR-701 400 mgTotal
Female20242266
Male433940122
09

Study locations

12 sites
  • Trius Study Site #011
    Dothan, Alabama 36301, United States
  • Trius Study site #001
    Chula Vista, California 91911, United States
  • Trius Study Site #009
    Long Beach, California 92708, United States
  • Trius Study site #002
    Oceanside, California 92056, United States
  • Trius Study site #010
    Pasadena, California 91105, United States
  • Trius Study site 007
    San Francisco, California 94143, United States
  • Trius Study site 003
    San Jose, California 95124, United States
  • Trius Study site 004
    Columbus, Georgia 31904, United States
  • Trius Study site #006
    Ludowici, Georgia 31316, United States
  • Trius Study site #005
    Savannah, Georgia 31406, United States
  • Trius Study site #012
    Springfield, Illinois 62701, United States
  • Trius study sie #008
    Detroit, Michigan 48202, United States
10

References and documents

Publications

  • Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Sep;56(9):4608-13. doi: 10.1128/AAC.00458-12. Epub 2012 Jun 11. PubMed 22687509 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2008 to primary completion in Feb 2009, 5 months.

Results were first posted in Aug 2014, 5 years 5 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2008
First posted
Sep 29, 2008
StartActual
Sep 17, 2008
Primary completionActual
Feb 24, 2009
CompletionActual
Feb 24, 2009
Results delay requested
Apr 2, 2014
Results first posted
Aug 7, 2014
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00761215
Responsible party
Sponsor
First posted
Sep 29, 2008
Start date
Sep 17, 2008
Primary completion
Feb 24, 2009
Completion
Feb 24, 2009
Results posted
Aug 7, 2014
Last update
Nov 25, 2019

Study contacts

Philippe Prokocimer, MD
study chair · Trius

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion